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Normal Dermal Ferrochelatase Activity Does Not Protect Human
Skin from Protoporphyrin-Induced Photosensitivity
To the Editor:
In the January issue of the Journal, Pawliuk et al (2005) report
that normal mice transplanted with bone marrow from a
mouse model of erythropoietic protoporphyria (EPP), BALB/
C-Fechm1Pas, have serum and erythrocyte protoporphyrin
concentrations that are as high as those in the photosensi-
tive donors and yet show only minimal photosensitivity and,
unlike the donors, do not develop liver damage. Further-
more, skin grafts from normal mice were not photosensitive
when implanted onto the backs of protoporphyric mice.
From these fascinating experiments, the authors
conclude that ‘‘in the presence of normal cellular levels of
hepatic and dermal ferrochelatase (FECH), elevated plasma
protoporphyrin levels alone are insufficient to generate
EPP-associated liver disease and significant photosensitiv-
ity’’ and suggest that their findings may provide new strat-
egies for treatment of EPP.
Can these observations be extended to humans? Clinical
observations suggest not. In their discussion, the authors
consider one argument against their hypothesis, namely the
occasional recurrence of disease in the donor liver after
transplantation for protoporphyric liver failure. But they, and
the accompanying Editorial (Lim, 2005), overlook another
clinical observation that is perhaps more pertinent to their
experiments.
The onset of EPP after the age of 40 y is very rare. When
it does occur, it is usually associated with myelodysplastic
syndrome (MDS) or a related disorder (Lim et al, 1992).
Recent molecular investigation of such cases has shown that
they develop EPP as a direct consequence of expansion in
their bone marrows of a clone of hemopoietic cells in which
deletion of one FECH allele leads to massive overproduction of
protoporphyrin (Aplin et al, 2001; Goodwin et al, 2002). For all
other tissues, evidence from analysis of germline DNA (Aplin
et al, 2001; Goodwin et al, 2002), and the observation that EPP
disappears after bone marrow transplantation (Lim et al, 1992),
suggests that FECH activity is likely to be normal, as would be
expected given the hematopoietic stem cell origin of MDS.
This experiment of nature in humans closely parallels
those described in mice by Pawliuk et al (2005). Yet, in spite
of their presumed normal dermal and hepatic FECH activ-
ities, these patients have severe skin photosensitivity (Lim
et al, 1992; Aplin et al, 2001), and one recently reported
case also developed acute protoporphyrin-induced liver
damage (Goodwin et al, 2002). Thus, in humans, an elevat-
ed plasma protoporphyrin concentration does seem to be
all that is required to produce severe skin photosensitivity.
Restoration of dermal FECH activities to normal may there-
fore have less promise as a treatment for EPP than the in-
triguing experiments of Pawliuk et al (2005) would suggest.
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Skin Ferrochelatase Levels and Photosensitivity
Philippe Leboulche and Micheline Mathews-Roth
Harvard University, Boston, Massachusetts, USA
Can the seemingly intuitive clinical counter-examples
provided by Elder rule out the possibility that restoring or
enhancing ferrochelatase activity in the skin of human
patients with the congenital erythropoietic protopor-
phyria (EPP) may prevent skin photosensitivity? We think
not.
Abbreviation: EPP, erythropoietic protoporphyria
Abbreviation: EPP, erythropoietic protoporphyria
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Recent progress has been achieved in our understanding
of the molecular mechanisms responsible for the sporadic
character of EPP-associated liver disease. For instance, a
recent study has shown that ‘‘patients with EPP who develop
liver disease usually have a mutation in one ferrochelatase
allele that alters enzyme function, together with a polymorph-
ism in the nonmutant allele that causes low gene expression’’
(Bloomer et al, 2005). This observation makes it unlikely that
the rare cases of recurrence of disease in a donor liver after
transplantation for protoporphyric liver failure occur in per-
fectly normal donor livers, and relapse may be caused by the
existence of a heterozygosity for a defective ferrochelatase
allele within the donor organ. This molecular lesion may re-
main clinically silent in the donor individual until the liver is
transplanted into a recipient with excess protoporphyric pro-
duction from the bone marrow compartment. Alternatively,
another molecularly unrelated pathological process may pre-
exist in the donor organ, thereby co-contributing to the es-
tablishment of liver disease. Studies in EPP mouse models of
various genetic backgrounds, although bearers of the same
ferrochelatase genetic mutation, have pointed to the major
role played by modifier genes on the occurrence and the
severity of associated liver disease (Abitbol et al, 2005). Al-
though these hypotheses remain to be documented, the
aforementioned observations do not directly support the
contention that restoring or enhancing local ferrochelatase
activity in a target organ will be ineffective at protecting it
from toxicity triggered by systemic excess in protoporphyrin.
It is also relevant to note that specific alterations of iron
metabolism, as in the targeted deletion of iron regulatory
protein 2, display a complex phenotype that, in part, mimics
EPP, with markedly increased levels of free protoporphyrin
IX, zinc-protoporphyrin, and skin photosensitivity (Cooper-
man et al, 2005). Interestingly, the rare cases of acquired,
late-onset EPP, cited by Elder are triggered by complex or
compounded genetic defects that include abnormalities of
iron metabolism such as sideroblastic anemia (Lim et al,
1992). In these genetically heterogeneous cases, it is thus
possible that enhanced or associated pathological proc-
esses may alter the clinical expression of the disease and/or
may be too pronounced to be surmounted by normal skin
ferrochelatase activity. Interestingly, the adult-onset EPP
patients seem to have higher protoporphyrin levels (11.9
and 112 mmol per liter in Aplin et al, 2001 and Goodwin et al,
2002, respectively) than many patients with the usual child-
hood-onset EPP (10 of 32 patients had less than 10 mmol
per liter in DeLeo et al, 1976). Even in cases of major serum
protoporphyrin elevation, it nevertheless remains possible
that cutaneous gene therapy would result in greater local
ferrochelatase activity than normal and would reach suffi-
cient levels to become effective for dermal protection.
Thus, the clinical examples reviewed by Elder may stim-
ulate further experimentation and discussion but do not per
se support his contention that symptomatic relief cannot be
obtained in certain patients with congenital EPP by eliciting
high levels of dermal ferrochelatase activity through local
gene transfer. The ideal way to treat EPP is to replace or
correct the defective ferrochelatase gene in hematopoietic
stem cells, either by gene therapy targeting the marrow
(Pawliuk et al, 1999) or by allogenic bone marrow trans-
plantation (Poh-Fitzpatrick et al, 2002). But these two meth-
ods involve significant risk at the present time, and thus
cannot be widely used in this relatively benign disorder. If
safe and effective gene transfer to the skin can be achieved,
relief may be obtained in a sub-population of EPP patients.
DOI: 10.1111/j.0022-202X.2005.23842.x
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Transglutaminase 5 Expression in Human Hair Follicle
To the Editor:
Transglutaminases (TG) are Ca2þ -dependent enzymes
catalyzing the formation of isodipeptide cross-links
among protein-bound lysines and glutamines, generat-
ing insoluble macromolecular aggregates (Greenberg
et al, 1991; Reichert et al, 1993; Steven and Steinert,
1994; Nemes and Steinert, 1999). TG are involved in
epidermal terminal differentiation (Rice and Green,
1977; Michel et al, 1992; Eckert et al, 1993; Candi et al,
1995).
Abbreviations: IRS, inner root sheath; ORS, outer root sheath; TG,
transglutaminases
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